Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice.

Beatriz Frade-Sosa Tarek Carlos Salman MonteJavier NarváezIrene PeraltaSebastian SandovalBerta MagallaresSergi HerediaNuria SapenaAnne Riveros-FrutosAlejandro OlivéHector CorominasJosefina Cortés-HernándezJosé A Gómez-Puerta

Published in: Lupus (2024)

Overall satisfaction, satisfaction with via of administration, and satisfaction with the time taken to receive BEL were higher for SQ BEL treatment. A switching SQ strategy is a reasonable alternative for BEL patients.

Keyphrases

clinical practice
end stage renal disease
systemic lupus erythematosus
randomized controlled trial
ejection fraction
newly diagnosed
low dose
combination therapy
peritoneal dialysis